# Study Evaluating the Effect of Lecozotan SR on the QTc Interval

> **NCT00499642** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Alzheimer Disease
- Healthy

## Interventions

- **DRUG:** Lecozotan SR
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT00499642
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** — (—)
- **Last updated:** 2007-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499642, "Study Evaluating the Effect of Lecozotan SR on the QTc Interval". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00499642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*